Episode Details

In this episode of the Trade to Black Podcast, we sit down with Doug Drysdale, Chief Executive Officer of Cybin, to discuss the recent milestones and future prospects of their novel psychedelic molecule, CYB003. #Cybin #Cybinstock #thedalesreport Key topics covered in this interview: - FDA’s Breakthrough Therapy Designation - Phase 2 Trial Success - The Road to Phase 3 - ICYB003’s fast onset of effects and its implications - Financial Strategy Insight Get a glimpse into the key milestones and developments expected in Cybin’s pipeline, focusing on Psilocybin, DMT/d-DMT, and Phenethylamines. Stay tuned to this episode to gain in-depth insights into Cybin's journey in revolutionizing the treatment of MDD with their innovative psychedelic therapies, following their recent announcement of FDA Breakthrough Therapy Designation for CYB003. Add us on: Facebook:   / thedalesreport   Twitter:   / thedalesreport   Instagram:   / dalesreport   Website: https://thedalesreport.com/ The information provided in this video is for educational purposes only and should not be considered as financial or investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions.